Rapid simultaneous acquisition of T1 and T2 mapping images using multishot double spin-echo EPI and automated variations of TR and TE (ms-DSEPI-T12)

Magnetic resonance imaging and ultrasound elastography in the context of preclinical pharmacological research: significance for the 3R principles

The 3Rs principles-reduction, refinement, replacement-are at the core of preclinical research within drug discovery, which still relies to a great extent on the availability of models of disease in animals. Minimizing their distress, reducing their number as well as searching for means to replace them in experimental studies are constant objectives in this area. Due to its non-invasive character in vivo imaging supports these efforts by enabling repeated longitudinal assessments in each animal which serves as its own control, thereby enabling to reduce considerably the animal utilization in the experiments. The repetitive monitoring of pathology progression and the effects of therapy becomes feasible by assessment of quantitative biomarkers. Moreover, imaging has translational prospects by facilitating the comparison of studies performed in small rodents and humans. Also, learnings from the clinic may be potentially back-translated to preclinical settings and therefore contribute to refining animal investigations. By concentrating on activities around the application of magnetic resonance imaging (MRI) and ultrasound elastography to small rodent models of disease, we aim to illustrate how in vivo imaging contributes primarily to reduction and refinement in the context of pharmacological research.

Primary Multiparametric Quantitative Brain MRI: State-of-the-Art Relaxometric and Proton Density Mapping Techniques

This review on brain multiparametric quantitative MRI (MP-qMRI) focuses on the primary subset of quantitative MRI (qMRI) parameters that represent the mobile ("free") and bound ("motion-restricted") proton pools. Such primary parameters are the proton densities, relaxation times, and magnetization transfer parameters. Diffusion qMRI is also included because of its wide implementation in complete clinical MP-qMRI application. MP-qMRI advances were reviewed over the past 2 decades, with substantial progress observed toward accelerating image acquisition and increasing mapping accuracy. Areas that need further investigation and refinement are identified as follows: (a) the biologic underpinnings of qMRI parameter values and their changes with age and/or disease and (b) the theoretical limitations implicitly built into most qMRI mapping algorithms that do not distinguish between the different spatial scales of voxels versus spin packets, the central physical object of the Bloch theory. With rapidly improving image processing techniques and continuous advances in computer hardware, MP-qMRI has the potential for implementation in a wide range of clinical applications. Currently, three emerging MP-qMRI applications are synthetic MRI, macrostructural qMRI, and microstructural tissue modeling.

Detection of Sulfatase Enzyme Activity with a CatalyCEST MRI Contrast Agent

A chemical exchange saturation transfer (CEST) MRI contrast agent has been developed that detects sulfatase enzyme activity. The agent produces a CEST signal at δ=5.0 ppm before enzyme activity, and a second CEST signal appears at δ=9.0 ppm after the enzyme cleaves a sulfate group from the agent. The comparison of the two signals improved detection of sulfatase activity.

Artifact-suppressed optimal three-dimensional T1 - and T2 *-weighted dual-echo imaging

PURPOSE

To develop a new artifact-suppressed optimal three-dimensional (3D) T₁ - and T₂ *-weighted dual-echo imaging.

METHODS

We optimized flip angles for 3D T₁ - and T₂ *-weighted imaging by conventional dual-echo in vivo experiments and computer simulations, and then implemented a dual-echo sequence with an echo-specific k-space reordering scheme to satisfy the optimal flip angles for both T₁ and T₂ * contrast. We also proposed two strategies to suppress ringing artifacts induced by the abrupt flip angle jumps in the proposed dual echo sequence: (i) implementing smooth transition regions and (ii) discarding the k-space regions of the abrupt flip angle jumps as dummy phase-encoding steps.

RESULTS

The optimal flip angles measured from experiments were different between T₁ - and T₂ *-weighted contrast, in agreement with simulations. The echo-specific k-space reordered dual-echo sequence showed optimal T₁ and T₂ * contrast simultaneously, but also showed ringing artifacts because of high flip-angle changes between k-space regions. The two proposed strategies effectively suppressed the ringing artifacts.

CONCLUSION

The proposed 3D dual-echo sequence provided optimal T₁ and T₂ * contrast simultaneously with no artifacts and thus is potentially applicable to routine clinical applications for simultaneous high resolution T₁ - and T₂ *-weighted imaging. Magn Reson Med 76:1504-1511, 2016. © 2015 International Society for Magnetic Resonance in Medicine.

Measuring T₂ and T₁, and imaging T₂ without spin echoes

During adiabatic excitation, the nuclear magnetization in the transverse plane is subject to T(2) (spin-spin) relaxation, depending on the pulse length τ. Here, this property is exploited in a method of measuring T(2) using the ratio of NMR signals acquired with short and long-duration self-refocusing adiabatic pulses, without spin-echoes. This Dual-τ method is implemented with B(1)-insensitive rotation (BIR-4) pulses. It is validated theoretically with Bloch equation simulations independent of flip-angle, and experimentally in phantoms. Dual-τT(2) measurements are most accurate at short T(2) where results agree with standard spin-echo measures to within 10% for T(2) ≤ 100 ms. Dual-τ MRI performed with a long 0° BIR-4 pre-pulse provides quantitative T(2) imaging of phantoms and the human foot while preserving desired contrast and functional properties of the rest of the MRI sequence. A single 0° BIR-4 pre-pulse can provide T(2) contrast-weighted MRI and serve as a "T(2)-prep" sequence with a lower B(1) requirement than prior approaches. Finally, a Tri-τ experiment is introduced in which both τ and flip-angle are varied, enabling measurement of T(2), T(1) and signal intensity in just three acquisitions if flip-angles are well-characterized. These new methods can potentially save time and simplify relaxation measurements and/or contrast-weighted NMR and MRI.

Ocular pharmacokinetic study using T₁ mapping and Gd-chelate- labeled polymers

PURPOSE

Recent advances in drug discovery have led to the development of a number of therapeutic macromolecules for treatment of posterior eye diseases. We aimed to investigate the clearance of macromolecular contrast probes (polymers conjugated with Gd-chelate) in the vitreous after intravitreal injections with the recently developed ms-DSEPI-T12 MRI and to examine the degradation of disulfide-containing biodegradable polymers in the vitreous humor in vivo.

METHODS

Intravitreal injections of model contrast agents poly[N-(2-hydroxypropyl)methacrylamide]-GG-1,6-hexanediamine-(Gd-DO3A), biodegradable (Gd-DTPA)-cystine copolymers, and MultiHance were performed in rabbits; their distribution and elimination from the vitreous after injections were determined by MRI.

RESULTS

Times for macromolecular contrast agents to decrease to half their initial concentrations in the vitreous ranged from 0.4-1.3 days post-injection. Non-biodegradable polymers demonstrated slower vitreal clearance than those of disulfide-biodegradable polymers. Biodegradable polymers had similar clearance as MultiHance.

CONCLUSIONS

Usefulness of T(1) mapping and ms-DSEPI-T12 MRI to study ocular pharmacokinetics was demonstrated. Results suggest an enzymatic degradation mechanism for the disulfide linkage in polymers in the vitreous leading to breakup of polymers in vitreous humor over time.

Single-shot T1 mapping using simultaneous acquisitions of spin- and stimulated-echo-planar imaging (2D ss-SESTEPI)

The conventional stimulated-echo NMR sequence only measures the longitudinal component while discarding the transverse component, after tipping up the prepared magnetization. This transverse magnetization can be used to measure a spin echo, in addition to the stimulated echo. Two-dimensional single-shot spin- and stimulated-echo-planar imaging (ss-SESTEPI) is an echo-planar-imaging-based single-shot imaging technique that simultaneously acquires a spin-echo-planar image and a stimulated-echo-planar image after a single radiofrequency excitation. The magnitudes of the spin-echo-planar image and stimulated-echo-planar image differ by T(1) decay and diffusion weighting for perfect 90 degrees radiofrequency and thus can be used to rapidly measure T(1). However, the spatial variation of amplitude of radiofrequency field induces uneven splitting of the transverse magnetization for the spin-echo-planar image and stimulated-echo-planar image within the imaging field of view. Correction for amplitude of radiofrequency field inhomogeneity is therefore critical for two-dimensional ss-SESTEPI to be used for T(1) measurement. We developed a method for amplitude of radiofrequency field inhomogeneity correction by acquiring an additional stimulated-echo-planar image with minimal mixing time, calculating the difference between the spin echo and the stimulated echo and multiplying the stimulated-echo-planar image by the inverse functional map. Diffusion-induced decay is corrected by measuring the average diffusivity during the prescanning. Rapid single-shot T(1) mapping may be useful for various applications, such as dynamic T(1) mapping for real-time estimation of the concentration of contrast agent in dynamic contrast enhancement MRI.

Rapid simultaneous acquisition of T1 and T2 mapping images using multishot double spin-echo EPI and automated variations of TR and TE (ms-DSEPI-T12)

A rapid method of simultaneous T(1) and T(2) measurement is presented which uses a segmented echo-planar readout with varying repetition times (TR) and echo times (TE). This method is useful in T(1) mapping for analysis of dynamic contrast enhanced MRI (DCE-MRI), where T(1) can be used to estimate contrast agent concentration. In the application of this method to dynamic imaging, the equilibrium magnetization is measured on pre-contrast images and incorporated into post-contrast T(1) calculations for improved accuracy. Simultaneous T(2) measurement allows correction of T(2) effects in the T(1) map which may occur at high contrast agent concentrations, and is performed without significant imaging time penalty. Phantom and in vivo results show the usefulness of this technique for analysis of contrast enhancement kinetics. Accurate rapid contrast agent concentration measurement may be useful for analyzing the distribution and kinetics of contrast agents or labeled pharmaceuticals.

MRI in ocular drug delivery

Conventional pharmacokinetic methods for studying ocular drug delivery are invasive and cannot be conveniently applied to humans. The advancement of MRI technology has provided new opportunities in ocular drug-delivery research. MRI provides a means to non-invasively and continuously monitor ocular drug-delivery systems with a contrast agent or compound labeled with a contrast agent. It is a useful technique in pharmacokinetic studies, evaluation of drug-delivery methods, and drug-delivery device testing. Although the current status of the technology presents some major challenges to pharmaceutical research using MRI, it has a lot of potential. In the past decade, MRI has been used to examine ocular drug delivery via the subconjunctival route, intravitreal injection, intrascleral injection to the suprachoroidal space, episcleral and intravitreal implants, periocular injections, and ocular iontophoresis. In this review, the advantages and limitations of MRI in the study of ocular drug delivery are discussed. Different MR contrast agents and MRI techniques for ocular drug-delivery research are compared. Ocular drug-delivery studies using MRI are reviewed.